IntroductionThis study aimed to compare two groups (9 years or younger [U-9] and 10 years or older [O-10]) of patients with fresh lumbar spondylolysis and elucidate their characteristics.MethodsThis study enrolled 51 elementary school students diagnosed with fresh lumbar spondylolysis through magnetic resonance imaging between March 2015 and March 2022. Study 1 included 10 and 46 patients in the early- and late-grade groups, respectively. Patient characteristics at disease onset (sex, presence or absence of spina bifida occulta [SBO] in the affected vertebra, vertebral level, unilaterality or bilaterality of lesions, presence of a contralateral terminal stage, and disease stage) were compared between the two groups. Meanwhile, Study 2 included 34 patients with confirmed successful or failed bone union. The bone union rates in both groups were compared, and the factors affecting bone union in the entire study cohort were examined.ResultsIn Study 1, the proportions of SBO, bilateral, and advanced stage cases were significantly higher in the U-9 group than in the O-10 group. In Study 2, the bone union rate was significantly lower in the U-9 group than in the O-10 group.ConclusionsThe proportions of SBO, bilateral, and advanced stage cases were significantly higher in the U-9 group than in the O-10 group. The bone union rate was significantly lower in the U-9 group than in the O-10 group.

01 Nov 2020·Neurochemical ResearchQ3 · MEDICINE

Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson’s Disease

Q3 · MEDICINE

Article

Author: Mathew, Bijo ; Saleem, Uzma ; Ahmad, Bashir ; Uddin, Md Sahab ; Parambi, Della Grace Thomas ; Manzar, Amna ; Anwar, Fareeha ; Itzaz, Aqsa ; Shah, Muhammad Ajmal ; Harilal, Seetha ; Kim, Hoon

Parkinson's disease (PD) is a neurodegenerative disorder of dopaminergic, noradrenergic, and serotonergic systems, in which dopamine, noradrenaline, and serotonin levels are depleted and lead to the development of motor and non-motor symptoms such as tremor, bradykinesia, weight changes, fatigue, depression, and visual hallucinations. Therapeutic strategies place much focus on dopamine replacement and the inhibition of dopamine metabolism. The present study was based on the known abilities of chalcones to act as molecular scaffolds that selectively inhibit MAO-B with the added advantage of binding reversibly. Recently, we synthesized a series of 26 chalcone compounds, amongst which (2E)-1-(2H-1,3-benzodioxol-5-yl)-3-(4-fluorophenyl)prop-2-en-1-one (O10) and (2E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(4-fluorophenyl)prop-2-en-1-one (O23) most inhibited MAO-B. Hence, the present study was performed to explore the molecular mechanisms responsible for the neuroprotective effect of O10 and O23 at varying doses such as 10, 20, and 30 mg/kg each in a haloperidol-induced murine model of PD. Both compounds were effective (though O23 was the more effective) at ameliorating extrapyramidal and non-motor symptoms in the model and improved locomotory and exploratory behaviors, reduced oxidative stress markers, and enhanced antioxidant marker and neurotransmitter levels. Furthermore, histopathological studies showed O10 and O23 both reduced neurofibrillary tangles and plaques to almost normal control levels.

100 Deals associated with O010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Nephropathies	Preclinical	DE	Boehringer Ingelheim GmbH	02 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

O010

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation